Navitor, the leading mTORC1 platform company, is developing targeted therapeutics designed tNavitor, the leading mTORC1 platform company, is developing targeted therapeutics designed to help patients increase their healthy years for uninterrupted quality of life. Navitor’s proprietary Navalog platform enables specific modulation of mTORC1, the gatekeeper of cellular metabolism and renewal, to address the disease processes that underlie a wide range of diseases, including prevalent conditions like depression, heart failure, chronic kidney disease and less common genetic disorders like polycystic kidney disease or rare forms of epilepsy. Navitor has partnered with Supernus to develop its sestrin ligand and mTORC1 activator, NV-5138, for depression. Navitor’s subsidiary Anakuria Therapeutics, Inc., and its Navalog platform of selective mTORC1 inhibitors have been acquired by Janssen Pharmaceuticals.
